Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · IEX Real-Time Price · USD
7.85
-0.35 (-4.27%)
Jul 2, 2024, 3:50 PM EDT - Market closed
Addex Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Addex Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for ADXN.
Recommendation Trends
| Rating | Feb '22 | Mar '22 | Apr '22 | May '22 | Jun '22 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 23, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $420 → $300 | Strong Buy | Maintains | $420 → $300 | +3,721.66% | May 31, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $560 → $420 | Strong Buy | Maintains | $560 → $420 | +5,250.32% | Feb 11, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $560 | Strong Buy | Initiates | $560 | +7,033.76% | Apr 21, 2021 |
Financial Forecast
Revenue This Year
1.53M
from 1.65M
Decreased by -7.11%
Revenue Next Year
1.53M
from 1.53M
EPS This Year
-0.07
from -0.14
EPS Next Year
-0.09
from -0.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 1.6M | 1.6M | 1.6M |
| Avg | 1.5M | 1.5M | 1.5M |
| Low | 1.5M | 1.5M | 1.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.4% | 2.9% | 2.9% |
| Avg | -7.1% | - | - |
| Low | -10.8% | -3.9% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.06 | -0.05 | -0.04 |
| Avg | -0.07 | -0.09 | -0.04 |
| Low | -0.08 | -0.12 | -0.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.